Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Clichy – page 13

181 clinical trials in Clichy, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Clichy at a glance
181
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

181 trials in Clichy

Open in trial search

Hepatocellular carcinoma

Not recruiting

Study on the Safety and Effectiveness of 166Holmium Radiation Therapy with Atezolizumab and Bevacizumab for Patients with Non-Resectable Liver Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Gustave Roussy

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Liver Cancer (Hepatocellular Carcinoma)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Hepatocellular carcinoma

Not recruiting

Study on Advanced Liver Cancer: Evaluating Livmoniplimab and Budigalimab in Patients Without Prior Systemic Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Chronic hepatitis B+1

Not recruiting

Study on Safety and Efficacy of Bepirovirsen and Drug Combination for Chronic Hepatitis B in Patients on Nucleos(t)ide Analogue Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Bepirovirsen
  • Sponsor:GlaxoSmithKline Biologicals

Hepatitis alcoholic

Not recruiting

Study on the Effects of INT-787 for Patients with Severe Alcohol-Associated Hepatitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:INT-787
  • Sponsor:Intercept Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study Comparing Standard Care and Targeted Treatment with Telemonitoring for Ulcerative Colitis Patients Using Adalimumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Cholangiocarcinoma

Not recruiting

Study of Durvalumab with Gemcitabine and Cisplatin for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Study on the Safety and Tolerability of Imdusiran and Durvalumab for Patients with Chronic Hepatitis B

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:AB-729
  • Sponsor:Arbutus Biopharma Inc.

Neuroendocrine tumour+1

Not recruiting

Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Octreotide
  • Sponsor:Advanced Accelerator Applications

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Rectal cancer

Not recruiting

Study on Chemotherapy and Pelvic Reirradiation for Patients with Recurrent Rectal Cancer Using Irinotecan, Levoleucovorin, Fluorouracil, Oxaliplatin, and Capecitabine

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Clichy

What the registry says about research in the country

01 Gastrointestinal Disorders

Innovative trials focusing on inflammatory bowel diseases and advanced treatment methods, including studies on Crohn's disease and ulcerative colitis using fecal microbiota transplantation as therapeutic approaches.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Short Bowel Syndrome

Research aims to improve patient outcomes through novel therapeutic interventions and treatment strategies.

02 Hepatobiliary Research

Comprehensive studies on liver diseases and biliary tract conditions, investigating new treatments for cirrhosis, portal hypertension, and various forms of liver cancer.

  • Hepatocellular Carcinoma
  • Biliary Tract Cancer
  • Liver Cirrhosis

Advanced therapeutic approaches combining immunotherapy and targeted treatments.

03 Pancreatic and Metabolic Disorders

Groundbreaking research on pancreatic cancer and metabolic conditions, evaluating novel drug combinations and treatment protocols.

  • Pancreatic Adenocarcinoma
  • Neuroendocrine Tumors
  • Metabolic Liver Disease

Focus on improving survival rates and treatment efficacy in advanced-stage diseases.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.